Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study-Reference-Cited by-同舟云学术

Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study

Published:2022-11 Issue:11 Volume:23 Page:1398-1408
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Merseburger Axel S,Attard Gerhardt,Åström Lennart,Matveev Vsevolod B,Bracarda Sergio,Esen Adil,Feyerabend Susan,Senkus Elżbieta,López-Brea Piqueras Marta,Boysen Gunther,Gourgioti Georgia,Martins Karla,Chowdhury Simon

Funder

Astellas Pharma

Pfizer

Astellas Pharma Inc

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Characterising the castration-resistant prostate cancer population: a systematic review;Kirby;Int J Clin Pract,2011

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

4. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrative Chinese-Western medicine strategy to overcome docetaxel resistance in prostate cancer;Journal of Ethnopharmacology;2024-09

2. Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial;European Urology Oncology;2024-09

3. Prostate-Specific Membrane Antigen PET/CT–Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer;Journal of Nuclear Medicine;2024-08-01

4. Efficacy and safety of androgen receptor inhibitors for treatment of advanced prostate cancer: A systematic review and network meta‐analysis;British Journal of Clinical Pharmacology;2024-07-11

5. Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials;Clinical Genitourinary Cancer;2024-06